Kirk Geale, PhD and Jessica Young will represent Quantify Research at the 42nd ISPE Annual Meeting, from 29 August to 2 September 2026.
This year’s theme, Unlocking the Power of Pharmacoepidemiology to Improve Patient Health, closely reflects our work.
Real world evidence supports evidence generation throughout the product lifecycle.
Before approval, RWE helps characterise disease burden, treatment patterns, and unmet need, sharpening our understanding of how new therapies may fit into current practice.
After regulatory approval, RWE supports post-authorisation safety studies, real world effectiveness research, and the evidence payers and HTA bodies need to make reimbursement decisions.
Quantify Research is currently supporting several PASS studies, work that speaks directly to this year’s theme of unlocking the power of pharmacoepidemiology to improve patient health.
📊Jessica Young | 29 August, 14:30–18:00
Jessica will join the faculty for the intermediate course:
Addressing Unmeasured Confounding through Study Design and Analysis
She will lead the module on quantitative bias analysis, exploring approaches for assessing bias from unmeasured confounding.
📈Kirk Geale, PhD Geale | 1 September, 13:00–14:30
Kirk will participate in the interactive panel:
Tomorrow’s Evidence 2.0: Replace, Refine, or Reframe the Evidence Pyramid?
His segment will focus on causal alignment, including target-trial emulation, estimands, intercurrent events, and evidence comparability.
Kirk also leads the RWE Business Unit at athagoras Group, supporting the continued development of real-world evidence expertise and capabilities across the group.
We look forward to discussions on how pharmacoepidemiology can produce more credible, transparent, and decision-ready evidence.
If you’re attending, Kirk and Jessica would welcome the chance to connect.
Will you be attending ISPE 2026 in Milan?